Restore Vision, a startup spun out of Keio University School of Medicine, has secured $8.2M in a Series b funding round to advance its work on intractable eye diseases. The company aims to develop treatments for conditions that currently lack effective prevention or cure, a critical gap in ophthalmic medicine.
This capital infusion bolsters Restore Vision's efforts to address diseases that leave ophthalmologists with no options, impacting hundreds of thousands of visually impaired patients in Japan and contributing to an estimated social cost of over 8 trillion yen.
